Autres langues Kymera Therapeutics, Inc.

Actions

KYMR

US5015751044

Marché Fermé - Nasdaq Autres places de cotation 22:00:02 01/05/2024			Varia. 5j.	Varia. 1 janv.
36,2 ^USD	+7,66 %		+2,80 %	+42,16 %

23/04	KYMERA THERAPEUTICS, INC. : Oppenheimer persiste à l'achat	ZM
08/04	Kymera Therapeutics, Inc. annonce des présentations scientifiques lors de la réunion annuelle de l'American Association for Cancer Research 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update	13:02
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2	25/04
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting	08/04
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting	08/04
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting	08/04
Kymera Therapeutics, Inc. Appoints Felix J. Baker to the Board	01/04
Kymera Therapeutics Insider Sold Shares Worth $14,912,376, According to a Recent SEC Filing	14/03
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting	11/03
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting	08/03
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting	08/03
Kymera Therapeutics to Participate in Upcoming March Investor Conferences	28/02
Kymera Therapeutics to Participate in Upcoming March Investor Conferences	28/02
Kymera Therapeutics Q4 Net Loss Narrows, Collaboration Revenue Rises	22/02
Kymera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	22/02
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	22/02
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22	15/02
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference	31/01
Kymera Therapeutics Insider Sold Shares Worth $300,470, According to a Recent SEC Filing	24/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Kymera Therapeutics, Inc.

Actions

KYMR

US5015751044

Autres langues

Filtres